Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HIV only Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

HIV Non-Occupational Post-Exposure Prophylaxis

NCT01855867
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

NCT01031472
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 15, 2026, 6:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Lamivudine for Solid Tumors

NCT06494579
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors
Interventions
Lamivudine, PD-L1 Blocker
Drug
Lead sponsor
Thomas Marron
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 15, 2026, 6:40 PM EDT
Terminated Early Phase 1 Interventional

Gene Transfer for HIV Using Autologous T Cells

NCT01153646
View directory record Official record
Conditions
HIV-1 Infection
Interventions
pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Results available

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

NCT04135937
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking
Interventions
Bupropion, Varenicline, Cognitive Behavioral Therapy, Nicotine Replacement Therapy, Relapse Prevention Text Messaging
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 15, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

NCT06269081
View directory record Official record
Conditions
HIV
Interventions
Supportive-Expressive Peer Social Support Group Intervention, Individual Strengths-Based Case Management Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

NCT02652546
View directory record Official record
Conditions
HIV, Inflammation
Interventions
Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 15, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

An Electronic Pillbox for People With HIV

NCT00071500
View directory record Official record
Conditions
HIV Infections
Interventions
MedSignals™
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Sep 15, 2026, 6:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Antiretroviral Therapy Selection: Comparing HIV Clinical Guidelines With HIV-ASSIST, an Online Decision-support Tool

NCT04080765
View directory record Official record
Conditions
Hiv
Interventions
HIV-ASSIST, DHHS guidelines
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Results available

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

NCT04982445
View directory record Official record
Conditions
HIV Infections
Interventions
CABENUVA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Evans, Georgia • East Lansing, Michigan • Novi, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Speed of Processing Training in Adults With HIV

NCT02758093
View directory record Official record
Conditions
HIV, Cognition - Other, Impaired Driving
Interventions
Speed of Processing Training, Internet Navigational
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

NCT01252641
View directory record Official record
Conditions
HIV, HIV Infection
Interventions
SB-728-T
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 15, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional Results available

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

NCT00496782
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc, Trofile Assay and HIV RNA quantification assay
Drug · Procedure
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Miami, Florida • Chicago, Illinois • Topeka, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 3 Interventional

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

NCT00002359
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
54
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project Jumpstart for Improving PrEP Care of Continuum Outcomes

NCT04201327
View directory record Official record
Conditions
HIV Infections
Interventions
Project Jumpstart
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Results available

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

NCT01214759
View directory record Official record
Conditions
HIV
Interventions
Truvada, Raltegravir
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 15, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs

NCT00005673
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 6:40 PM EDT
Withdrawn Phase 2 Interventional

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

NCT05582694
View directory record Official record
Conditions
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Interventions
UB-421
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 15, 2026, 6:40 PM EDT
Completed No phase listed Observational

Cross Sectional CFAR HIV/COVID-19 Study

NCT04514016
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
3 Years to 25 Years
Enrollment
64 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 15, 2026, 6:40 PM EDT
Recruiting Phase 1 Interventional

B7-H3.CD28Z.CART in Solid Tumors

NCT07358260
View directory record Official record
Conditions
Pediatric Solid Tumor, Neuroblastoma
Interventions
B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Robbie Majzner
Other
Eligibility
9 Months to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 15, 2026, 6:40 PM EDT